H. Lundbeck A/S Presents Neurology Data
Analysis based on 6 articles · First reported Apr 13, 2026 · Last updated Apr 13, 2026
The announcement of new neurology data by Lundbeck at a major medical conference could positively impact investor sentiment towards the company, especially if the data for bocunebart, eptinezumab, and bexicaserin are perceived as strong, potentially leading to increased stock value. This event highlights the ongoing innovation in the pharmaceutical industry, particularly in brain health, which could attract broader market attention to the sector.
Lundbeck announced that it will present new data from its neurology portfolio at the American Academy of Neurology Annual Meeting 2026 in Chicago, United States. The presentations will cover migraine, developmental and epileptic encephalopathies (DEEs), and multiple system atrophy (MSA). Highlights include new Phase 1 data on bocunebart, an investigational monoclonal antibody for migraine prevention, and further data on eptinezumab (VYEPTI), an approved intravenous anti-CGRP preventive treatment for migraine. Additionally, Lundbeck will present 12-month results from the PACIFIC trial for bexicaserin, an investigational treatment for seizures in DEEs, which has received Breakthrough Therapy designation from the United States — Food and Drug Administration and in China. Findings from a Delphi consensus study in MSA will also be shared. Johan Luthman emphasized Lundbeck's focus on translating neuroscience insights into drug development programs for areas with unmet patient needs.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard